Y-mAbs Therapeutics (YMAB) Stock Chart & Stock Price History $4.54 -0.16 (-3.40%) As of 02:20 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Y-mAbs Therapeutics Stock Price Performance The Y-mAbs Therapeutics (YMAB) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 62.42%, with a year-to-date return of -42.02%. In the past month, the stock has decreased 3.61%, reflecting recent market activity. As of the latest close, Y-mAbs Therapeutics traded at $4.70 with a market cap of $212.82 million and volume of 212,172 shares. Five years ago, the stock traded at $43.20, representing a 89.49% decrease over that period. At the time, it had a market cap of $1.81 billion and a volume of 431,233 shares. Receive YMAB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-7.54%1 Month Performance-3.61%3 Month Performance-5.61%Year-To-Date Performance-42.02%1 Year Performance-62.42%5 Year Performance-89.49% YMAB Stock Chart for Monday, June, 30, 2025 YMAB Chart by TradingView Y-mAbs Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/27/2025$4.80$4.70-2.08%$4.78$4.58212,172 shs$212.82 million06/26/2025$4.91$4.80-2.24%$4.97$4.73126,155 shs$217.34 million06/25/2025$5.13$4.91-4.29%$5.24$4.87200,436 shs$222.33 million06/24/2025$4.72$5.13+8.69%$5.33$4.68529,410 shs$232.29 million06/23/2025$4.41$4.72+7.03%$4.75$4.28152,743 shs$213.74 million06/20/2025$4.63$4.41-4.75%$4.70$3.90764,472 shs$199.69 million06/19/2025$4.63$4.63$4.96$4.5593,749 shs$209.65 million06/18/2025$4.80$4.63-3.54%$4.96$4.5593,749 shs$209.67 million06/17/2025$4.94$4.80-2.83%$4.98$4.74132,833 shs$217.36 million06/16/2025$4.71$4.94+4.88%$4.94$4.61100,374 shs$223.70 million Get the Latest News and Ratings for YMAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 06/13/2025$4.63$4.71+1.73%$4.88$4.46472,812 shs$213.29 million06/12/2025$4.93$4.63-6.09%$4.92$4.59161,686 shs$209.67 million06/11/2025$5.11$4.93-3.52%$5.19$4.91153,696 shs$223.25 million06/10/2025$5.08$5.11+0.59%$5.29$5.04107,093 shs$231.40 million06/09/2025$5.27$5.08-3.61%$5.47$5.03153,236 shs$230.04 million06/06/2025$5.10$5.27+3.33%$5.41$5.14109,604 shs$238.65 million06/05/2025$4.96$5.10+2.82%$5.12$4.75144,157 shs$230.95 million06/04/2025$4.87$4.96+1.85%$5.16$4.80193,855 shs$224.61 million06/03/2025$4.74$4.87+2.74%$4.96$4.69119,615 shs$220.53 million06/02/2025$4.71$4.74+0.64%$4.92$4.55215,613 shs$214.65 million05/30/2025$4.75$4.71-0.84%$4.75$4.49253,129 shs$213.29 million05/29/2025$4.62$4.75+2.81%$5.00$4.55302,142 shs$215.10 million Related Companies ORIC Stock Chart PRAX Stock Chart COGT Stock Chart CMRX Stock Chart CDMO Stock Chart AVXL Stock Chart SNDX Stock Chart AVBP Stock Chart QURE Stock Chart IMNM Stock Chart Receive YMAB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:YMAB) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
